Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

December 31, 2017

Conditions
Leukoma
Interventions
DEVICE

RHCIII-MPC cornea

Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.

DEVICE

Donor cornea

Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.

Trial Locations (1)

500034

L V Prasad Eye Institute, Centre for Ocular Regeneration, Hyderabad

All Listed Sponsors
collaborator

Linkoeping University

OTHER_GOV

lead

L.V. Prasad Eye Institute

OTHER

NCT02424006 - Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty | Biotech Hunter | Biotech Hunter